Loading...
CG Oncology, Inc. Common stock
CGON•NASDAQ
Healthcare
Biotechnology
$26.31
$-0.38(-1.42%)
CG Oncology, Inc. Common stock (CGON) Financial Performance & Income Statement Overview
Review CG Oncology, Inc. Common stock’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
458.33%
↑ 458.33%
Operating Income Growth
-106.80%
↓ 106.80%
Net Income Growth
-81.12%
↓ 81.12%
Operating Cash Flow Growth
-72.32%
↓ 72.32%
Operating Margin
-20302.27%
↓ 20302.27%
Gross Margin
98.94%
↑ 98.94%
Net Profit Margin
-15945.17%
↓ 15945.17%
ROE
-16.71%
↓ 16.71%
ROIC
-19.05%
↓ 19.05%
CG Oncology, Inc. Common stock (CGON) Income Statement & Financial Overview
Review CG Oncology, Inc. Common stock's (CGON) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $456000.00 | $43000.00 | $111000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $7000.00 |
| Gross Profit | $0.00 | $456000.00 | $43000.00 | $104000.00 |
| Gross Profit Ratio | $0.00 | $1.00 | $1.00 | $0.94 |
| R&D Expenses | $27.47M | $26.80M | $19.62M | $18.47M |
| SG&A Expenses | $14.79M | $11.71M | $8.72M | $7.49M |
| Operating Expenses | $42.26M | $38.51M | $28.34M | $25.96M |
| Total Costs & Expenses | $0.00 | $38.51M | $28.34M | $25.96M |
| Interest Income | $0.00 | $6.25M | $7.89M | $6.94M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $21000.00 | $7000.00 |
| EBITDA | -$42.20M | -$38.05M | -$28.27M | -$25.85M |
| EBITDA Ratio | -$83.44 | -$657.53 | -$232.91 | |
| Operating Income | -$42.20M | -$38.05M | -$28.30M | -$25.85M |
| Operating Income Ratio | -$83.44 | -$658.02 | -$232.91 | |
| Other Income/Expenses (Net) | $0.00 | $6.25M | $7.89M | $6.95M |
| Income Before Tax | $0.00 | -$31.80M | -$20.41M | -$18.90M |
| Income Before Tax Ratio | $0.00 | -$69.73 | -$474.53 | -$170.29 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $0.00 | -$31.80M | -$20.41M | -$18.90M |
| Net Income Ratio | $0.00 | -$69.73 | -$474.53 | -$170.29 |
| EPS | -$0.45 | -$0.49 | -$0.30 | -$0.28 |
| Diluted EPS | -$0.45 | -$0.49 | -$0.30 | -$0.28 |
| Weighted Avg Shares Outstanding | $76.19M | $64.82M | $67.14M | $66.65M |
| Weighted Avg Shares Outstanding (Diluted) | $76.19M | $64.82M | $67.14M | $66.65M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan